Radix Polygoni Multiflori Praeparata and Dioscorea Bulbifera Rhizome Decoctions Display Combined Effects Detected by a Three-Probe Drug Cocktail with Substrates of Rat Hepatic Cytochrome P450 Enzymes

Li Jiang, Pingping Shan, Hui Yu, Jiayuan Tao, Chunyan Gong, Guoqing Shen

Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China.

DOI: 10.4236/pp.2014.57083                

Abstract

Objectives: Radix Polygoni Multiflori Praeparata (RPMP) and Dioscorea Bulbifera Rhizomes (DBR) are used in Chinese herbal medicine and have been frequently reported for adverse reactions on liver. In this research, we aimed to evaluate in vivo effects of RPMP and DBR on rat cytochrome P450 enzymes (CYP1A2, CYP2E1 and CYP3A2) with their respective substrates as probes. Methods: Rats were orally administered RPMP, DBR and RPMP/DBR combination at 12, 10 and (12 + 10) g/kg, respectively, or saline as a control, once daily for 7 days. Thereafter, a cocktail containing 10 mg/kg caffeine, 20 mg/kg chlorzoxazone and 10 mg/kg dapsone was tail vein injected to rats. At defined time points, plasma drug concentrations were simultaneously evaluated by HPLC. Pharmacokinetic parameters simulated by DAS software were used to assess RPMP and/or DBR effects on cytochrome P450 enzymes activity. ANOVA and Dunnett’s test were used for data analysis. Results: Caffeine metabolism was enhanced in RPMP animals and reduced after pretreatment with DBR, but no effect was observed in RPMP/DBR combination group. Chlorzoxazone and dapsone metabolism was enhanced in both RPMP and DBR groups and consequently in combination group. The data suggested that RPMP independently induces rat CYP1A2, CYP2E1 and CYP3A2 activity, while DBR independently inhibits activity of rat CYP1A2 and induces that of CYP2E1 and CYP3A2. RPMP/DBR combination showed no significant benefit compared with the two drugs alone and even showed a neutralized effect in CYP1A2 activity. Conclusions: Caution is needed when RPMP and/or DBR are co-administered with drugs metabolized by human CYP1A2, CYP2E1 and CYP3A4.

Keywords

Radix Polygoni Multiflori Praeparata, Dioscorea Bulbifera Rhizomes, Cytochrome P450, Herb-Drug Interactions, Three-Probe Drug Cocktail

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Bent, S. (2008) Herbal Medicine in the United States: Review of Efficacy, Safety, and Regulation: Grand Rounds at University of California, San Francisco Medical Center. Journal of General Internal Medicine, 23, 854-859. http://dx.doi.org/10.1007/s11606-008-0632-y
[2]	Commission of Chinese Pharmacopoeia (2010) Pharmacopoeia of the People’s Republic of China. China Medico-Pharmaceutical Science & Technology Publishing House, Beijing, 164-165.
[3]	Du, L.X., Luo, M.M. and Liu, S.M. (2007) Advances in Modern Toxicology Studies on Dioscorea bulbifera. Liaoning University of Traditional Chinese Medicine, 9, 71-72.
[4]	Li, J.H., Zhang, X.H. and Chi, H.H. (2000) Study on Anti-Tumor Effect of Different Bulbifera Extracts. Journal of Hebei Jiaotong Vocational and Technical College, 17, 5-7.
[5]	Gao, H.Y., Wu, L.J. and Kuroyanagi, M. (2001) Seven Compounds from Dioscorea bulbifera L. (Natural Medicine Note). Nature Medicine, 277-281.
[6]	Xu, Y., Chen, C.C., Yang, L., Wang, J.M., Ji, L.L., et al. (2011) Evaluation on Hepatotoxicity Caused by Dioscorea bulbifera Based on Analysis of Bile Acids. Acta pharmaceutica Sinica, 46, 39-44.
[7]	Chen, X.L., Wu, S.H. and Zhao, J.B. (1998) Suppression Effect of the Bulbifera Alcohol Extract on Mice Xenografts Tumor. Journal of the Fourth Military Medical University, 19, 354-355.
[8]	Suo, Q. and Cui, L.R. (2008) Study on Anti-Tumor Effect of Serum Containing Bulbifera and Angelica. China Medical Technologies, 15, 113-114.
[9]	Tan, X.Q., Yuan, J.L., Chen, H.S., Wang, J.Y. and Wang, J.S. (2003) Study on Antiinflamtory Components in Dioscorea bulbifera Rhizome. Second Military Medical University, 24, 677-679.
[10]	Rao, Y.Z., Wen, T.L. and Zhao, H.M. (2010) Study on Anti-Inflammatory Effect of Methanol Extracts from Dioscorea bulbifera L. Anhui Agricultural Science Bulletin, 16, 64-65.
[11]	Xu, Y.Z., Bai, X.Q. and Zhou, Q. (1998) Study on Virus Inhibitory Effect of Ethanol Extract of Dioscorea bulbifera. Chemical and Pharmaceutical Bulletin, 23, 535-537.
[12]	Zhu, F.L. and Jia, L. (2006) Research Progress of Dioscorea bulbifera. Shizhen Med Mat Med Res, 17, 851-853.
[13]	Chen, Y., Cheng, M. and Liu, C.X. (2004) Present Development and Prospect of Hepatotoxic Chinese Materia Medica. Chinese Traditional and Herbal Drugs, 35, 1315-1317.
[14]	Zhao, Y., Piao, H.Y. and Chu, X.J. (2010) Based on Efficacy and Material Base of Toxicity Research Progress. Heilongjiang Medical Journal, 34, 821-824.
[15]	Wang, J.M., Cui, D.P. and Cui, Y. (2011) Research Progress in Chemical Components, Pharmacological Actions and Toxicity of Diterpene Lactones Isolated from Dioscoreae bulbifera L. Rhizome. Journal of Chinese Materia Medica, 26, 1319-1321.
[16]	Wang, J.M., Lei, J.F., Ji, L.L., Liu, H., Wang, Z.T., et al. (2011) Research Progress and Strategy in Toxicity of Dioscorea bulbifera Rhizome with Main Bioactivity of Antitumor Action. Chinese Journal of Experimental Traditional Medical Formulae, 12, 256-259.
[17]	Yu, J., Xie, J., Mao, X.J., Wang, M.J., Li, N., et al. (2011) Hepatoxicity of Major Constituents and Extractions of Radix Polygoni Multiflori and Radix Polygoni Multiflori Praeparata. Journal of Ethnopharmacology, 137, 1291-1299. http://dx.doi.org/10.1016/j.jep.2011.07.055
[18]	Bush, T.M., Rayburn, K.S., Holloway, S.W., Sanchez-Yamamoto, D.S., Allen, B.L., et al. (2007) Adverse Interactions between Herbal and Dietary Substances and Prescription Medications: A Clinical Survey. Alternative Therapies in Health and Medicine, 13, 30-35.
[19]	Han, Y.L., Yu, Q., Meng, X.L., Li, D., Bian, K., et al. (2009) Inhibition of Dengzhan-Xi-Xin Injection on Rat Liver Microsomal CYP3A. Chinese Journal of Clinical Pharmacology and Therapeutics, 14, 891-895
[20]	Yang, Q.H., Meng, X.Q. and Li, Y.L. (1997) Observation on the Effect of Compound Danshen Inducing Human CYP 450 1A2. Journal of Harbin Medical University, 31, 295-296.
[21]	Liu, S.J., Ju, W.Z., Chen, W.K., Xu, L.J., Xiong, N.N., et al. (2010) Influence of Xue-Shuan-Tong Injection on P450 Activities Using a Cocktail Method. Chinese Pharmaceutical Journal, 45, 115-118.
[22]	Klingenberg, M. (1958) Pigments of Rat Liver Microsomes. Archives of Biochemistry and Biophysics, 75, 376-386. http://dx.doi.org/10.1016/0003-9861(58)90436-3
[23]	Guengerich, F.P. (1992) Characterization of Human Cytochrome P450 Enzymes. The FASEB Journal, 6, 745-748.
[24]	Isin, E.M. and Guengerich, F.P. (2007) Complex Reactions Catalyzed by Cytochrome P450 Enzymes. Biochimica et Biophysica Acta (BBA)-General Subjects, 1770, 314-329. http://dx.doi.org/10.1016/j.bbagen.2006.07.003
[25]	Slaughter, R.L. and Edwards, D.J. (1995) Recent Advances: The Cytochrome P450 Enzymes. The Annals of Pharmacotherapy, 29, 619-624.
[26]	Kerremans, A.L. (1996) Cytochrome P450 Isoenzymes—Importance for the Internist. The Netherlands Journal of Medicine, 48, 237-243. http://dx.doi.org/10.1016/0300-2977(96)00002-2
[27]	Lewis, D.F. (2003) P450 Structures and Oxidative Metabolism of Xenobiotics. Pharmacogenomics, 4, 387-395. http://dx.doi.org/10.1517/phgs.4.4.387.22752
[28]	Daly, A.K. (2004) Pharmacogenetics of the Cytochromes P450. Current Topics in Medicinal Chemistry, 4, 1733-1744. http://dx.doi.org/10.2174/1568026043387070
[29]	Ingelman-Sundberg, M. (2004) Pharmacogenetics of Cytochrome P450 and Its Applications in Drug Therapy: The Past, Present and Future. Trends in Pharmacological Sciences, 25, 193-200. http://dx.doi.org/10.1016/j.tips.2004.02.007
[30]	Fan, H.R., He, F., Li, Q.S., Huang, Y.R., Wei, G.L., et al. (2004) Study on Influence of Ginsenoside Re on Cytochrome P450 Isoforms by Cocktail Approach Using Probe Drugs, Caffeine, Chlorzoxazone, Omeprazole And dapsone in Rats. Asian Journal of Drug Metabolic and Pharmacokinetics, 4, 91-98.
[31]	Sharma, A., Pilote, S., Bélanger, P.M., Arsenault, M. and Hamelin, B.A. (2004) A Convenient Five-Drug Cocktail for the Assessment of Major Drug Metabolizing Enzymes: A Pilot Study. British Journal of Clinical Pharmacology, 58, 288-297. http://dx.doi.org/10.1111/j.1365-2125.2004.02162.x
[32]	Martignoni, M., Groothuis, G.M. and de Kanter, R. (2006) Species Differences between Mouse, Rat, Dog, Monkey and Human CYP-Mediated Drug Metabolism, Inhibition and Induction. Expert Opinion on Drug Metabolism & Toxicology, 6, 875-894. http://dx.doi.org/10.1517/17425255.2.6.875
[33]	Alikhan, A., Felsten, L.M., Daly, M. and Petronic-Rosic, V. (2011) Vitiligo: A Comprehensive Overview. Part I. Introduction, Epidemiology, Quality of Life, Diagnosis, Differential Diagnosis, Associations, Histopathology, Etiology, and Work-Up. Journal of the American Academy of Dermatology, 65, 473-491. http://dx.doi.org/10.1016/j.jaad.2010.11.061
[34]	Li, W.Y., Yu, W.D., Dong, Q., Wang, P. and Chen, Q.X. (2004) A Complex Prescription for Vitiligo Activates Mitochondrial ATP Synthase-6 Expression in B-16 Murine Melanoma Cells. Journal of Ethnopharmacology, 92, 193-196. http://dx.doi.org/10.1016/j.jep.2004.03.021
[35]	Shimada, T., Mimura, M., Inoue, K., Nakamura, S.I., Oda, H., et al. (1997) Cytochrome P450-Dependent Drug Oxidation Activities in Liver Microsomes of Various Animal Species Including Rats, Guinea Pigs, Dogs, Monkeys, and Humans. Archives of Toxicology, 71, 401-408. http://dx.doi.org/10.1007/s002040050403
[36]	Carrillo, J.A., Christensen, M., Ramos, S.I., Alm, C., Dahl, M.L., et al. (2000) Evaluation of Caffeine as an in Vivo Probe for CYP1A2 Using Measurements in Plasma, Saliva, and Urine. Therapeutic Drug Monitoring, 22, 409-417. http://dx.doi.org/10.1097/00007691-200008000-00008
[37]	Faber, M.S., Jetter, A. and Fuhr, U. (2005) Assessment of CYP1A2 Activity in Clinical Practice: Why, How, and When? Basic & Clinical Pharmacology & Toxicology, 97, 125-134. http://dx.doi.org/10.1111/j.1742-7843.2005.pto_973160.x
[38]	Lee, A.M., Joshi, M., Yue, J. and Tyndale, R.F. (2006) Phenobarbital Induces Monkey Brain CYP2E1 Protein but Not Hepatic CYP2E1, in Vitro or in Vivo Chlorzoxazone Metabolism. European Journal of Pharmacology, 552, 151-158. http://dx.doi.org/10.1016/j.ejphar.2006.09.006
[39]	Porubsky, P.R., Meneely, K.M. and Scott, E.E. (2008) Structures of Human Cytochrome P-450 2E1. Insights into the Binding of Inhibitors and Both Small Molecular Weight and Fatty Acid Substrates. The Journal of Biological Chemistry, 283, 33698-33707. http://dx.doi.org/10.1074/jbc.M805999200
[40]	Obach, R.S., Zhang Q.Y., Dunbar, D. and Kaminsky, L.S. (2001) Metabolic Characterization of the Major Human Small Intestinal Cytochrome P450s. Drug Metabolism and Disposition, 29, 347-352.
[41]	Kanazu, T., Yamaguchi, Y., Okamura, N., Baba, T. and Koike, M. (2004) Model for the Drug-Drug Interaction Responsible for CYP3A Enzyme Inhibition. II: Establishment and Evaluation of Dexamethasone-Pretreated Female Rats. Xenobiotica, 34, 403-413. http://dx.doi.org/10.1080/00498250410001685746
[42]	Gurley, B.J., Gardner, S.F., Hubbard, M.A., Williams, D.K., Gentry, W.B., et al. (2002) Cytochrome P450 Phenotypic Ratios for Predicting Herb-Drug Interactions in Humans. Clinical Pharmacology & Therapeutics, 72, 276-287. http://dx.doi.org/10.1067/mcp.2002.126913
[43]	Zhou, S.F., Lim, L.Y. and Chowbay, B. (2004) Herbal Modulation of P-Glycoprotein. Drug Metabolism Reviews, 36, 57-104. http://dx.doi.org/10.1081/DMR-120028427